Reyataz (atazanavir) NDC 0003-3638

NDC codes

FDA NDC Directory

Product NDC (as listed)0003-3638Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00003-3638Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0003-3638-10	00003363810	30 PACKET in 1 CARTON (0003-3638-10) / 1 POWDER in 1 PACKETMarketed from Dec 19, 2014

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Reyataz
Generic name (nonproprietary): atazanavir
Active ingredients: Atazanavir sulfate — 50 mg/1
Dosage form: Powder
Route: Oral
Labeler: E.R. Squibb & Sons, L.L.C.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 206352
Marketing start: Dec 19, 2014
Listing expires: Dec 31, 2026
Other FDA classes: Cytochrome P450 2C8 Inhibitors (Mechanism)Cytochrome P450 3A Inhibitors (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)HIV Protease Inhibitors (Mechanism)UDP Glucuronosyltransferases Inhibitors (Mechanism)UGT1A1 Inhibitors (Mechanism)
Identifiers: Product ID 0003-3638_510c2d51-4943-401c-a008-ea22f61c6938SPL ID 510c2d51-4943-401c-a008-ea22f61c6938SPL set ID 165cff62-b284-4a27-a65d-9ec8a5bfcdd8RxCUI 402093, 402094, 402246, 402247, 664741, 664743, 1598985, 1598989UNII 4MT4VIE29PUPC 0300033624120, 0300033622126
Pharmacologic class: Protease Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400003363810 followed by a unit qualifier and the quantity

Package 00003-3638-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 5, 2024.

Indications (excerpt from the label)

REYATAZ ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 3 months and older weighing at least 5 kg. Limitations of Use: • REYATAZ is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [see Use in Specific Populations (8.4) ] . • Use of REYATAZ with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see Microbiology (12.4) ] . REYATAZ is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)